Cancer News and Research

Latest Cancer News and Research

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, announces that data from the second Phase III trial of microplasmin (TG-MV-007) for the non-surgical treatment of vitreomacular adhesion (VMA), are to be presented at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress.

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

1 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

Cell Therapeutics to retire all Notes with maturity in 2010

Cell Therapeutics, Inc. today announced that it has deposited $39.3 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 4% convertible senior subordinated notes, which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest.

1 Jul 2010

Ronin, Hcf-1 bind together to control gene program that stimulates growth of stem cells

Ronin, crucial to the self-renewal of embryonic stem cells, and a co-regulator called Hcf-1, binds to a small strand of DNA called a hyperconserved enhancer element to control a gene "program" that stimulates growth of the stem cells and may even play a role in cancer, said a group of researchers led by Baylor College of Medicine in a current report in the journal Genes and Development.

1 Jul 2010

USPTO grants Semafore method patent for PI3K inhibitors

Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.

1 Jul 2010

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

The Florida Biomedical Research Program has awarded $2 million in biomedical research grants to three scientists from the Florida campus of The Scripps Research Institute.

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

A new study from researchers in Ottawa and Toronto suggests that a commonly used type of bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body. The study, published in the American Journal of Respiratory and Critical Care Medicine, shows that these cells can triple survival rates in an experimental model of sepsis.

1 Jul 2010

Highly specific assay developed to detect ERG alterations in prostate cancer

Researchers at the Uniformed Services University of the Health Sciences Center for Prostate Disease Research, in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center, have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.

1 Jul 2010

Secondhand smoke exposure during pregnancy causes permanent genetic damage in newborns

Newborns of non-smoking moms exposed to secondhand smoke during pregnancy have genetic mutations that may affect long-term health, according to a University of Pittsburgh Graduate School of Public Health study published online in the Open Pediatric Medicine Journal. The abnormalities, which were indistinguishable from those found in newborns of mothers who were active smokers, may affect survival, birth weight and lifelong susceptibility to diseases like cancer.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

Latest health disparity report examines trend of higher tobacco use among LGBT community

The American Lung Association's latest health disparity report, Smoking Out a Deadly Threat: Tobacco Use in the LGBT Community, examines the trend of higher tobacco use among the lesbian, gay, bisexual and transgender community and the need for additional research specific to this community.

1 Jul 2010

Varian, Brainlab expand partnership to incorporate Novalis technology with TrueBeam STx system

Varian Medical Systems and Brainlab today announced the expansion of their partnership to incorporate Novalis technology and other Novalis Radiosurgery Program elements with the recently launched TrueBeam STx system. The expanded suite of products will be badged "Novalis powered by TrueBeam STx."

1 Jul 2010

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

Rubicon Genomics today announced that its PicoPlex linear whole genome amplification technology was proven to be effective in an independent clinical study organized by the European Society for Human Reproduction and Embryology. At a press conference during its 26th Annual Meeting in Rome, ESHRE reported the success of its "groundbreaking proof of principle study" showing that a new approach incorporating PicoPlex could more accurately detect and characterize chromosomal abnormalities in human eggs.

1 Jul 2010

New Stanford Hospital to include one entire floor of hybrid rooms

Whether it's called a hybrid room or an interventional platform, Room 9 at Stanford Hospital & Clinics is that singular space where a patient can stay in one place to be diagnosed and treated, either with surgery or the latest interventional procedure, in an environment as sterile as an operating room, with all-important imaging devices, microscopes and monitors right at hand.

1 Jul 2010

Cancer News and Research

Latest Cancer News and Research

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

AstraZeneca announces new support program for patients on ARIMIDEX

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Cell Therapeutics to retire all Notes with maturity in 2010

Ronin, Hcf-1 bind together to control gene program that stimulates growth of stem cells

USPTO grants Semafore method patent for PI3K inhibitors

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

Highly specific assay developed to detect ERG alterations in prostate cancer

Secondhand smoke exposure during pregnancy causes permanent genetic damage in newborns

Endo responds to FDA Complete Response letter for FORTESTA NDA

New guide to get pregnant

Latest health disparity report examines trend of higher tobacco use among LGBT community

Varian, Brainlab expand partnership to incorporate Novalis technology with TrueBeam STx system

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

New Stanford Hospital to include one entire floor of hybrid rooms

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in